Except for targeting mutant IDHs, metabolic inhibitors are potentially active regardless of tumor genetic subtype and thus beneficial to the large majority of men with CRPC who are not currently candidates for precision medicine (e.g., DNA repair defects for PARP inhibitors or CDK12 loss for immunotherapy) (138, 163). Here, CDK12 is linked to neoplasm.